Clicky

HEMOSTEMIX INC.(2VF0)

Description: Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.


Keywords: Biotechnology Pain Stem Cell Cell Therapy Cardiovascular Disease Vascular Disease Stem Cell Therapy Acute Pain Peripheral Neuropathy Angina Peripheral Arterial Disease Peripheral Artery Disease Stem Cell Therapies Angina Pectoris Treatment Of Vascular Diseases

Home Page: hemostemix.com

707-7th Avenue SW
Calgary, AB T2P 3H6
Canada
Phone: 905-580-4170


Officers

Name Title
Mr. Thomas A. Smeenk B.A., BA Hons Co-Founder, President, CEO & Director
Ms. Christina Wu CPA Interim Chief Financial Officer
Mr. Peter Pavlin Vice President of Operations
Dr. Fraser C. Henderson Sr., M.D. Chief Medical Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks